<DOC>
	<DOCNO>NCT02258074</DOCNO>
	<brief_summary>The COMBINE clinical trial pilot study evaluate effect nicotinamide lanthanum carbonate serum phosphate fibroblast growth factor 23 ( FGF23 ) patient Chronic Kidney Disease ( CKD ) stag 3-4 .</brief_summary>
	<brief_title>The COMBINE Study : The CKD Optimal Management With BInders NicotinamidE</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Patients estimate glomerular filtration rate ( eGFR ) 2045 ml/min/1.73m2 2 . Age 1885 year 3 . Serum phosphate ≥ 2.8 mg/dL 4 . Platelet count ≥ 125,000/mm3 5 . Able provide consent 6 . Able travel study visit 7 . Able eat least two meal day 8 . In opinion site investigator , willing able follow study treatment regimen comply site investigator 's recommendation . 1 . History allergic reaction nicotinamide , niacin ( exclude flushing ) , multivitamin preparation , lanthanum carbonate 2 . Liver disease , define know cirrhosis image physician diagnosis , document alcohol use &gt; 14 drinks/week , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase , total bilirubin concentration &gt; 2 time upper limit local laboratory reference range 3 . Creatine kinase ( CK ) concentration &gt; 2 time upper limit local laboratory reference range 4 . Major hemorrhagic event within past six month require inpatient admission 5 . Blood platelet transfusion within past six month 6 . Secondary hyperparathyroidism ( PTH &gt; 5 time upper limit normal range laboratory ) currently take cinacalcet ( Sensipar ) 7 . Current , clinically significant malabsorption , determine discretion site investigator 8 . Anemia ( screen Hg &lt; 9.0 g/dl ) 9 . Serum albumin &lt; 2.5 mg/dl 10 . Anticipated initiation dialysis kidney transplantation within 12 month assess discretion site investigator . 11 . Use immunosuppressive medication ( stable oral steroid ≤ 10 mg prednisone/day inhale steroid exempt ) 12 . In opinion site investigator , active abuse alcohol drug 13 . Recent ( within last 14 day ) initiation change dose treatment 1,25 ( OH ) 2 vitamin D active vitamin D analogue ( paricalcitol hectorol ) . Patients stable dos agent initiate 14 day prior screen eligible participate . 14 . Current recent treatment ( within last 14 day ) phosphate binder niacin/nicotinamide &gt; 100 mg/day 15 . Current participation another clinical trial interventional research 16 . Currently take investigational drug 17 . Institutionalized individual , include prisoner nursing home resident 18 . Malignancy require therapy within 2 year ( basal squamous cell skin carcinoma localize prostate cancer exempt )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>